ARGENX SE (ARGX.BR) Stock Price, Quote, News and Overview
EBR:ARGX - Euronext Brussels - NL0010832176 - Common Stock - Currency: EUR
ARGX.BR Quote, Performance and Key Statistics
ARGENX SE
EBR:ARGX (2/5/2025, 9:27:05 AM)
629.4
-2 (-0.32%)
The current stock price of ARGX.BR is 629.4 EUR. In the past month the price increased by 0.38%. In the past year, price increased by 69.05%.
ARGX.BR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 18.69 | 323.32B | ||
| AMG.DE | AMGEN INC | 14.96 | 149.57B | ||
| 1AMGN.MI | AMGEN INC | 14.81 | 148.09B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 937.76 | 118.34B | ||
| GIS.DE | GILEAD SCIENCES INC | 21.97 | 117.44B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 27.07B | ||
| IDP.DE | BIOGEN INC | 8.75 | 20.15B | ||
| 0QF.DE | MODERNA INC | N/A | 13.30B | ||
| 1MRNA.MI | MODERNA INC | N/A | 13.08B | ||
| ALEMS.BR | EUROPEAN MEDICAL SOLUTIONS S | N/A | 9.95B | ||
| GLPG.AS | GALAPAGOS NV | 6.99 | 1.44B | ||
| NVV1.DE | NOVAVAX INC | N/A | 1.30B |
Related stock screener links
About ARGX.BR
Company Profile
argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,148 full-time employees. The company went IPO on 2014-07-10. The company creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
Company Info
ARGENX SE
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND NL
Employees: 1148
Company Website: https://www.argenx.com/
Investor Relations: https://www.argenx.com/investors
Phone: 31763030
ARGX.BR FAQ
What is the stock price of ARGX.BR?
The current stock price of ARGX.BR is 629.4 EUR.
What is the symbol for ARGENX SE stock?
The exchange symbol of ARGENX SE is ARGX and it is listed on the Euronext Brussels exchange.
On which exchange is ARGX.BR stock listed?
ARGX.BR stock is listed on the Euronext Brussels exchange.
Is ARGX.BR a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ARGX.BR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ARGX.BR.
Does ARGX.BR stock pay dividends?
ARGX.BR does not pay a dividend.
When does ARGX.BR stock report earnings?
ARGX.BR will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of ARGX.BR?
ARGX.BR does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.85).
ARGX.BR Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ARGX.BR. When comparing the yearly performance of all stocks, ARGX.BR is one of the better performing stocks in the market, outperforming 97.3% of all stocks.
ARGX.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ARGX.BR. ARGX.BR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ARGX.BR Financial Highlights
Over the last trailing twelve months ARGX.BR reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS increased by 78.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.77% | ||
| ROE | -6.5% | ||
| Debt/Equity | 0.01 |
ARGX.BR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ARGX.BR. The Buy consensus is the average rating of analysts ratings from 24 analysts.
For the next year, analysts expect an EPS growth of 127.93% and a revenue growth 76.75% for ARGX.BR